Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)
CUSIP: 29384C108
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 38,346,880
- Total 13F shares
- 24,778,477
- Share change
- -1,094,382
- Total reported value
- $301,833,417
- Price per share
- $12.18
- Number of holders
- 35
- Value change
- -$12,927,920
- Number of buys
- 12
- Number of sells
- 31
Quarterly Holders Quick Answers
What is CUSIP 29384C108?
CUSIP 29384C108 identifies TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29384C108:
Top shareholders of TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ROCHE HOLDING LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,813,525
|
$44,988,265 | — | 02 Nov 2021 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
12%
|
4,704,419
|
$44,174,000 | — | 31 Mar 2022 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
12%
|
4,425,784
|
$41,558,000 | — | 31 Mar 2022 | |
| 5AM Venture Management, LLC |
13F
|
Company |
11%
|
4,408,379
|
$41,395,000 | — | 31 Mar 2022 | |
| Redmile Group, LLC |
3/4/5
13F
|
10%+ Owner · Company |
5.1%
from 13F
|
1,954,420
|
$31,251,176 | — | 02 Nov 2021 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
6.6%
|
2,543,102
|
$23,816,000 | — | 31 Mar 2022 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
6.5%
|
2,494,714
|
$23,425,000 | — | 31 Mar 2022 | |
| FMR LLC |
13F
|
Company |
2.3%
|
876,794
|
$8,233,000 | — | 31 Mar 2022 | |
| StepStone Group LP |
13F
|
Company |
2%
|
761,277
|
$7,148,000 | — | 31 Mar 2022 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.7%
|
663,694
|
$6,133,000 | — | 31 Mar 2022 | |
| 72 Investment Holdings, LLC |
13F
|
Company |
1.3%
|
509,023
|
$4,780,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.2%
|
445,520
|
$4,184,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
445,455
|
$4,183,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.1%
|
430,404
|
$4,041,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.46%
|
177,733
|
$1,668,000 | — | 31 Mar 2022 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.45%
|
173,582
|
$1,630,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.39%
|
151,194
|
$1,420,000 | — | 31 Mar 2022 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
106,000
|
$995,000 | — | 31 Mar 2022 | |
| MOORE CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.27%
|
105,000
|
$986,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.24%
|
90,258
|
$847,000 | — | 31 Mar 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.18%
|
68,704
|
$646,000 | — | 31 Mar 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.17%
|
64,399
|
$604,000 | — | 31 Mar 2022 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.15%
|
57,675
|
$542,000 | — | 31 Mar 2022 | |
| Walleye Capital LLC |
13F
|
Company |
0.12%
|
44,652
|
$419,000 | — | 31 Mar 2022 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.11%
|
41,175
|
$393,140 | — | 31 Mar 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.06%
|
21,933
|
$206,000 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
20,871
|
$196,000 | — | 31 Mar 2022 | |
| Ghisallo Capital Management LLC |
13F
|
Company |
0.04%
|
15,000
|
$141,000 | — | 31 Mar 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.04%
|
13,872
|
$130,000 | — | 31 Mar 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
11,800
|
$111,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
8,361
|
$78,000 | — | 31 Mar 2022 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
5,223
|
$49,000 | — | 31 Mar 2022 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
4,959
|
$47,000 | — | 31 Mar 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
4,934
|
$46,000 | — | 31 Mar 2022 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
4,880
|
$46,000 | — | 31 Mar 2022 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.01%
|
4,446
|
$42,000 | — | 31 Mar 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
2,485
|
$23,000 | — | 31 Mar 2022 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
2,285
|
$21,000 | — | 31 Mar 2022 | |
| STRS OHIO |
13F
|
Company |
0.01%
|
2,100
|
$19,000 | — | 31 Mar 2022 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
1,709
|
$16,000 | — | 31 Mar 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,447
|
$13,000 | — | 31 Mar 2022 | |
| AMALGAMATED BANK |
13F
|
Company |
0%
|
1,350
|
$13,000 | — | 31 Mar 2022 | |
| Amalgamated Financial Corp. |
13F
|
Company |
0%
|
1,350
|
$13,000 | — | 31 Mar 2022 | |
| State of Wyoming |
13F
|
Company |
0%
|
1,060
|
$10,000 | — | 31 Mar 2022 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
848
|
$8,000 | — | 31 Mar 2022 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
708
|
$7,000 | — | 31 Mar 2022 | |
| NISA INVESTMENT ADVISORS, LLC |
13F
|
Company |
0%
|
700
|
$7,000 | — | 31 Mar 2022 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
646
|
$6,000 | — | 31 Mar 2022 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
413
|
$4,000 | — | 31 Mar 2022 | |
| Carole Nuechterlein |
3/4/5
|
Director |
—
class O/S missing
|
11,918
|
— | — | 02 Jun 2022 |
Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q2 2022
As of 30 Jun 2022,
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,778,477 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, MPM ASSET MANAGEMENT LLC, 5AM Venture Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Redmile Group, LLC, WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, VANGUARD GROUP INC, TCG Crossover Management, LLC, and StepStone Group LP.
This page lists
35
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
48
Q2 2022 holders
35
Holder diff
-13
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.